| Public | DB:GX1B |
| Website | tapimmune.com |
| Category | BioTech |
| Phone | 866-359-7541 |
| ir@TapImmune.com | |
| Employees | |
| Founded | 1999 |
| TOTAL | $866k |
| FUNDING TOTAL | $866k |
| Venture Round, 5/10 Iroquois Capital | $866k |
TapImmune Inc., a development stage company, engages in the discovery and development of immunotherapeutics for the treatment of cancer, infectious diseases, autoimmune disorders, and transplant tissue rejection. The company focuses on conducting studies using its transporters of antigen processing (TAP) gene technology in combination with an adeno virus. Its products include TAP cancer vaccine used for the treatment of breast cancer, prostate cancer, lung cancer, liver cancer, melanoma, renal cancer, and colorectal cancer. The company also develops vaccines for infectious diseases using its TAP gene technology. TapImmune has strategic relationships with University of British Columbia, Crucell Holland B.V., SAFC Pharma, Inc., and National Institute of Allergy and Infectious Diseases. The company was founded in 1999 and is based in Vancouver, Canada.
